Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer umbrella study tests multiple drug combos

NCT ID NCT03337698

Terminated Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested several immunotherapy-based drug combinations in people with metastatic non-small cell lung cancer. It included two groups: those who had not received prior treatment and those whose cancer had worsened after standard therapy. The trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Atezolizumab, Cobimetinib, RO6958688, Docetaxel, CPI-444
What this could lead to
If successful, this could identify effective immunotherapy combinations for advanced lung cancer patients who have not responded to standard treatments.
What could go wrong
The trial was terminated early, so results are limited. It is an early-phase study with small groups, so any findings are preliminary and may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

  • Barts Cancer Institute

    London, E1 2AT, United Kingdom

  • Blacktown Hospital

    Blacktown, New South Wales, 2148, Australia

  • Centre Georges Francois Leclerc

    Dijon, 21079, France

  • Centre Léon Bérard

    Lyon, 69008, France

  • Chaim Sheba Medical Center

    Ramat Gan, 52620-00, Israel

  • Clínica Universidad de Navarra

    Pamplona, Navarre, 31008, Spain

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley

    Las Vegas, Nevada, 89169, United States

  • Fundación Jimenez Díaz

    Madrid, 28040, Spain

  • Hopital de la Timone

    Marseille, 13005, France

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital Regional Universitario de Malaga

    Málaga, 29010, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario HM Sanchinarro-CIOCC

    Madrid, 28050, Spain

  • Hospital Universitario La Paz

    Madrid, 280146, Spain

  • Institut De Cancerologie De L'Ouest

    Saint-Herblain, 44115, France

  • Institut Régional du Cancer de Montpellier

    Montpellier, 34298, France

  • Institut Universitaire du Cancer de Toulouse-Oncopole

    Toulouse, 31100, France

  • Korea University Guro Hospital

    Seoul, 08308, South Korea

  • Peter Mac Callum Cancer Center

    East Melbourne, Victoria, 3002, Australia

  • Rabin Medical Center

    Petah Tikva, 4941492, Israel

  • Rambam Medical Center

    Haifa, 3109601, Israel

  • Royal Marsden Hospital

    Sutton, SM2 5PT, United Kingdom

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, NE1 4LP, United Kingdom

  • University Hospitals Case Medical Center

    Cleveland, Ohio, 44106, United States

  • University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC)

    Songpa-gu, 05505, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.